An increased rate of discontinuation due to immune-mediated adverse events was seen in the trial's coformulation arm.

Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase ...

Merck & Co., Inc. (MRK) announced Monday the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 ...

The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could ...

Merck’s blockbuster PD-1 inhibitor pembrolizumab (Keytruda) may be effective against endometrial cancer in some settings, but ...

Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial ...

Tiffany Bostwick, P.A., discussed the importance of communication and education around adverse effects for both oncology ...

The phase 3 KEYNOTE-B21 study missed its primary end point, as pembrolizumab plus chemotherapy did not improve disease-free ...

Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results ...

Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the vibostolimab ...